TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

15 Sep 2021 13:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

14 Sep 2021 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Sep 2021 14:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

07 Sep 2021 05:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

16 Aug 2021 04:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2021 Financial Results

29 Jul 2021 13:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2021 Financial Results

22 Jul 2021 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jul 2021 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

04 Jun 2021 05:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 Jun 2021 05:00:01 By Nasdaq GlobeNewswire